Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026
Sarepta Therapeutics, Inc. (SRPT)
A forensic read on Sarepta Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-2.8
Distress distance
Clean
Earnings quality
4
Forensic signals
-53.5%
ROE
15.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Sarepta Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -2.8, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-30.9%
FY2025
Return on invested capital.Return on invested capital is -30.9% in the latest fiscal year, against -9.2% in FY2023, having run between -30.9% and 8.9% across FY2023–FY2025 with no direction held. After-tax operating profit was ($212M) in FY2023 and ($553M) in FY2025, with operating income at -21.5% of revenue in FY2023, 11.5% in FY2024 and -31.8% in FY2025. The capital base behind it cannot be compared across FY2023–FY2025: short-term debt is tagged in one of those two fiscal years and not the other, and an untagged line enters this calculation as zero, so any change in the base would be a change in what the filer tagged. $195M of the $1.8B base at FY2025 is short-term investments (10.9%) — securities held beside cash, which the base keeps because only cash is subtracted from it; they earn the balance sheet's yield, which is not in the operating profit above, so the loss on the operating capital is larger than this rate shows.
FCF ($307M)
FY2025
Shareholder returns.Returned $25M to shareholders (buybacks + dividends) in FY2025, but free cash flow was ($307M) after capex — there was no free cash flow to fund the payout from at all, and operating cash flow itself was negative or zero that year too. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.
+4.1%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +8% over the last 2 years to FY2025 (+4.1%/yr). The count is growing — 92.4M shares in FY2023, 100.1M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~4.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~8%.
6% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 6% of revenue in FY2025 — about $1.23 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 4.1% a year across FY2023–FY2025, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$2.20B
Revenue Growth YoY+15.6%
Revenue CAGR (2yr)+33.0%
Net Margin-32.5%
Free Cash Flow-$307.5M
Return on Equity-53.5%
Debt / Equity0.73x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Sarepta Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?